MedTrace Logo

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

NCT07393659 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2026-08-14

No results posted yet for this study

Summary

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

Conditions

  • HIV Infections

Interventions

DRUG

Fostemsavir

Participants receive oral tablets with the dosages depending on the weight of the participants.

DRUG

Dolutegravir (DTG)/ Lamivudine (3TC)

Participants receive oral tablets with the dosages depending on the weight of the participants.

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-21
Primary Completion
2032-09-14
Completion
2032-09-14

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07393659 on ClinicalTrials.gov